Latest Report on Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2020

Research By Markets adds Market Research Report - Latest Report on Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2020

For detailed information: https://www.researchbymarkets.com/report/non-alcoholic-fatty-liver-disease-nafld-pipeline-review-h2-2020-625909.html

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2020

Summary

Non Alcoholic Fatty Liver Disease – Pipeline Review, H2 2020, provides an overview of the Non Alcoholic Fatty Liver Disease (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

Report Highlights

Non Alcoholic Fatty Liver Disease – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 26, 14, 2, 37 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 6 molecules, respectively.

Non Alcoholic Fatty Liver Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (Gastrointestinal)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
89bio Inc
ABIONYX Pharma SA
Afimmune Biopharma Ltd
Albireo Pharma Inc
Amicogen Inc
AptamiR Therapeutics Inc
AstraZeneca Plc
Azure Health Technology Ltd
BBN Cardio Therapeutics
Beijing Fogangren Bio-Pharm Tech Co Ltd
Betagenon AB
Bird Rock Bio Inc
Cadila Healthcare Ltd
Can-Fite BioPharma Ltd
Carmot Therapeutics Inc
ChemomAb Ltd
China NT Pharma Group Co Ltd
Corbus Pharmaceuticals Inc
Corcept Therapeutics Inc
Curacle Co Ltd
Dr. Falk Pharma GmbH
DURECT Corp
Eli Lilly and Co
Eternygen GmbH
Evgen Pharma Plc
F. Hoffmann-La Roche Ltd
Fujian Cosunter Pharmaceutical Co Ltd
Galmed Pharmaceuticals Ltd
GemVax & KAEL Co Ltd
Gilead Sciences Inc
Hanmi Pharmaceuticals Co Ltd
Hepion Pharmaceuticals Inc
HK inno.N Corp
Huons Co Ltd
Immuron Ltd
Inorbit Therapeutics AB
Inventiva
Ionis Pharmaceuticals Inc
J2H Biotech
Kinomedica Pty Ltd
KoBioLabs Inc
Kowa Co Ltd
Kyorin Pharmaceutical Co Ltd
Liminal BioSciences Inc
Lynkogen Inc
Macrophage Pharma Ltd
Macrophage Therapeutics Inc
Mallinckrodt Plc
Metacrine Inc
Micelle BioPharma Inc
Mina Therapeutics Ltd
Nano Intelligent Biomedical Engineering Corp
NeuroBo Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Nivarta Inc
Novartis AG
NovMetaPharma Co Ltd
NuSirt Biopharma Inc
Oncocross Co Ltd
PegBio Co Ltd
Pfizer Inc
PharmaKing Co Ltd
Phenex Pharmaceuticals AG
PTC Therapeutics Inc
Renova Therapeutics Inc
Salix Pharmaceuticals Ltd
Shenzhen HighTide Biopharmaceutical Ltd
SparkBioPharma Inc
Sveikatal Inc
T3D Therapeutics Inc
TaiwanJ Pharmaceuticals Co Ltd
Terns Pharmaceuticals Inc
TES Pharma SRL
Theratechnologies Inc
Vidasym Inc
Viking Therapeutics Inc


For queries regarding this report: https://www.researchbymarkets.com/sample-request/625909

Contact Us:
ResearchByMarkets.com
Sales Desk
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via ritesh@researchbymarkets.com. *Market Research News is a part of Research By Markets.